CF
ALXO icon

Corebridge Financial’s ALX Oncology ALXO Stock Holding History

Corebridge Financial’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,878
Closed -$10.5K – 135
2025
Q1 		$10.5K Sell
16,878
-251
-1% -$301 ﹤0.01% 2969
2024
Q4 		$28.6K Sell
17,129
-1,093
-6% -$1.68K ﹤0.01% 2921
2024
Q3 		$33.2K Buy
18,222
+451
+3% +$1.68K ﹤0.01% 2941
2024
Q2 		$107K Buy
+17,771
New +$219K ﹤0.01% 2562

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Corebridge Financial's ALXO Position: Q2 2025 in Review

Corebridge Financial sold out of ALX Oncology (ALXO) in Q2 2025, closing a stake of 16,878 shares — an estimated $10.5K sold.

Corebridge Financial first reported a position in ALXO in Q2 2024 and held it in 4 quarters. The position peaked at $107K in Q2 2024. 61 funds tracked by Wall St. Rank hold ALXO as of Q2 2025.

  • Corebridge Financial reported no remaining ALX Oncology position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 16,878 ALX Oncology shares in Q2 2025, an estimated $10.5K.
  • Corebridge Financial first reported a position in ALX Oncology in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's ALX Oncology position peaked at $107K in Q2 2024.
  • 61 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.